Amphista Therapeutics Welcomes New Chief Executive Officer
Amphista Therapeutics has made a significant advancement by appointing Antony Mattessich as its new Chief Executive Officer (CEO). This decision is anticipated to accelerate the company’s growth, especially in the development of its innovative Targeted Glue™ protein degraders, which are on the verge of entering clinical trials.
Exciting Milestones and Future Growth
The appointment of Mattessich follows an impressive year for Amphista in 2024. The company recently celebrated three major milestones that underscore its pioneering capabilities: demonstrating in vivo efficacy, successfully targeting and degrading proteins within the central nervous system (CNS), and revealing a novel mechanism of action for protein degradation.
Background of Antony Mattessich
Antony Mattessich comes to Amphista with a wealth of experience, having successfully guided numerous programs from initial discovery through clinical development and into successful commercialization. Over his career, he has raised more than $750 million to support various biotechnology ventures. Prior to joining Amphista, he was the President and CEO of Ocular Therapeutix, a Nasdaq-listed company, where he played a key role in developing treatments for conditions like Wet Age-Related Macular Degeneration.
Mattessich's Vision for Amphista
Upon his appointment, Mattessich shared his excitement about his new role at Amphista. He stated, "2024 is a pivotal year for Amphista, and I am thrilled to be part of a company with such unique technology in the targeted protein degradation sector at this exciting stage of its development. My goal will be to evolve Amphista's portfolio to transform innovative research into groundbreaking treatments that enhance patients' lives."
Support from the Chairman
Joshua Brumm, Chairman of Amphista's Board of Directors, echoed Mattessich's enthusiasm, saying, "Antony’s extensive experience in drug development, combined with his insights into capital markets, aligns perfectly with our strategy to advance our leading assets into clinical trials following this year’s compelling new data on in vivo efficacy and CNS activity. We are excited to welcome Antony during such a transformative time for Amphista."
Recent Scientific Progress
Earlier in 2024, Amphista announced the success of its next-generation bifunctional protein degraders. Additionally, the company introduced a new mechanism of action for degrading BRD9, a promising target in oncology. This innovative strategy sets itself apart from traditional cereblon- or VHL-based technologies, showcasing Amphista’s commitment to advancing its groundbreaking targeted protein degradation (TPD) medicines.
About Amphista Therapeutics
Amphista Therapeutics is committed to transforming treatment options for patients facing severe conditions, including cancer and neurodegenerative disorders, by advancing next-generation targeted protein degradation therapies. Utilizing proprietary warhead chemistry and mechanistic expertise, Amphista is developing bifunctional Targeted Glue® agents with exceptional properties. This innovative approach not only aims to create first-or-best-in-class drugs but also seeks to expand the application of TPD therapies beyond traditional methods. The company was founded as a spin-out from the University of Dundee, driven by Professor Alessio Ciulli's expertise, and is supported by prominent investors and strategic partners.
For More Information
If you have any inquiries, please contact:
Amphista Therapeutics
John Goodall
Email: info@amphista.com
ICR Consilium
Amber Fennell, Namrata Taak, Emily Johnson
Email: amphista@consilium-comms.com
Tel: +44 (0)20 3709 5813
Frequently Asked Questions
What is Amphista Therapeutics?
Amphista Therapeutics is a biopharmaceutical company dedicated to developing next-generation targeted protein degradation therapies to address challenging diseases.
Who is Antony Mattessich?
Antony Mattessich is the newly appointed CEO of Amphista Therapeutics, bringing extensive experience in drug development and company leadership.
What significant achievements has Amphista made in 2024?
In 2024, Amphista successfully demonstrated in vivo efficacy, targeted protein degradation in the CNS, and introduced new mechanisms for its therapies.
What technologies does Amphista employ?
Amphista utilizes proprietary warhead chemistry to develop bifunctional Targeted Glue® agents aimed at enhancing the effectiveness of TPD treatments.
How can I learn more about Amphista's developments?
For more information, you can visit Amphista's official website or reach out to their communication team directly.
